System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Andrew Furness is an expert in Oncology at Royal Marsden NHS Foundation Trust (United Kingdom). Andrew Furness has authored 117 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 455 (community average: 125). How the SLR is computed.

LeadR Profile

Andrew Furness Royal Marsden NHS Foundation Trust United Kingdom
455 ScienceLeadR Reputation 455

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Surgery - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2026
Source: PubMed

National Health Service

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 117

Citations

Citations: 13 261 1st author: 3 Last author: 9 Unique author: 2

Main journals

J Clin Oncol 9
Ann Oncol 6
Cancer Cell 6
J Immunother Cancer 6
Cancer Discov 5

Best Journals

J Clin Oncol 5
Cancer Cell 4
Nat Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.
PMID 42640561 — melanoma, neoplasms, liver, therapeutics, prognosis, uveal melanoma		Oncologist20260
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
PMID 42350045 — lymphocytes, lymphocytes, tumor-infiltrating, melanoma, neoplasms, immunotherapy, immune checkpoint inhibitors, response evaluation criteria in solid tumors, therapeutics		J Immunother Cancer20260
The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic review.
PMID 41862835 — cells, lymphocytes, melanoma, neoplasms, therapeutics		BMC Cancer20260
The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.
PMID 41855016 — therapeutics		Ann Surg Oncol20260
ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.
PMID 41855018		Ann Surg Oncol20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 4
Phase 1/Phase 2 2
Phase 1 1

By status:

Active not recruiting 2
Recruiting 2
Completed 1
Enrolling by invitation 1
Unknown 1

By type:

Observational 4
Interventional 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 2
multicentric5to9 2
multicentricup10 2

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
UK ENcorafenib and BInimetinib Real world Study in Melanoma
NCT07022457 — quality of life, melanoma, therapeutics, mutation		N/AActive not recruiting2025
The CAPER Trial A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma
NCT04262427 — cells, cyclophosphamide, drug therapy, carcinoma, renal cell, immunoglobulins, solutions, antibodies, monoclonal, programmed cell death 1 receptor, cell death, chemotherapy, carcinoma		Phase 1/Phase 2Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS